NWRNClinical Trials•businesswire•August 12, 2025 at 11:00 AM

Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)

Sentiment:Negative (35)

Summary

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia (TRS).

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 12, 2025 by businesswire